Key points are not available for this paper at this time.
PCSK9i are safe and effective in clinical practice, leading to very high adherence and persistence to therapy, and achievement of recommended LDL-C target in most patients, especially when used as combination therapy.
Gargiulo et al. (2023) studied this question.